Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Conserved and variant epitopes of Plasmodium vivax Duffy binding protein as targets of inhibitory monoclonal antibodies.

Ntumngia FB, Schloegel J, Barnes SJ, McHenry AM, Singh S, King CL, Adams JH.

Infect Immun. 2012 Mar;80(3):1203-8. doi: 10.1128/IAI.05924-11.

2.

Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II.

Ntumngia FB, Schloegel J, McHenry AM, Barnes SJ, George MT, Kennedy S, Adams JH.

Vaccine. 2013 Sep 13;31(40):4382-8. doi: 10.1016/j.vaccine.2013.07.002.

3.

Design and immunogenicity of a novel synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein.

Ntumngia FB, Adams JH.

Clin Vaccine Immunol. 2012 Jan;19(1):30-6. doi: 10.1128/CVI.05466-11.

4.

Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding Protein.

Chen E, Salinas ND, Huang Y, Ntumngia F, Plasencia MD, Gross ML, Adams JH, Tolia NH.

Proc Natl Acad Sci U S A. 2016 May 31;113(22):6277-82. doi: 10.1073/pnas.1600488113.

5.

Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies.

Chootong P, Ntumngia FB, VanBuskirk KM, Xainli J, Cole-Tobian JL, Campbell CO, Fraser TS, King CL, Adams JH.

Infect Immun. 2010 Mar;78(3):1089-95. doi: 10.1128/IAI.01036-09.

6.

Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II.

Ntumngia FB, Barnes SJ, McHenry AM, George MT, Schloegel J, Adams JH.

Clin Vaccine Immunol. 2014 Sep;21(9):1215-23. doi: 10.1128/CVI.00205-14.

7.

Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein.

Ntumngia FB, King CL, Adams JH.

Int J Parasitol. 2012 Nov;42(12):1055-62. doi: 10.1016/j.ijpara.2012.09.006. Review.

8.

The association of Duffy binding protein region II polymorphisms and its antigenicity in Plasmodium vivax isolates from Thailand.

Chootong P, McHenry AM, Ntumngia FB, Sattabongkot J, Adams JH.

Parasitol Int. 2014 Dec;63(6):858-64. doi: 10.1016/j.parint.2014.07.014.

9.

Natural acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein (PvDBP-II) equally block erythrocyte binding of homologous and heterologous expressed PvDBP-II on the surface of COS-7 cells.

Valizadeh V, Zakeri S, Mehrizi AA, Mirkazemi S, Djadid ND.

Med Microbiol Immunol. 2016 Feb;205(1):85-95. doi: 10.1007/s00430-015-0429-7.

PMID:
26243337
10.

Characterization of inhibitory anti-Duffy binding protein II immunity: approach to Plasmodium vivax vaccine development in Thailand.

Chootong P, Panichakul T, Permmongkol C, Barnes SJ, Udomsangpetch R, Adams JH.

PLoS One. 2012;7(4):e35769. doi: 10.1371/journal.pone.0035769.

11.
12.

Antigenic drift in the ligand domain of Plasmodium vivax duffy binding protein confers resistance to inhibitory antibodies.

VanBuskirk KM, Cole-Tobian JL, Baisor M, Sevova ES, Bockarie M, King CL, Adams JH.

J Infect Dis. 2004 Nov 1;190(9):1556-62.

13.

Structural analysis of the synthetic Duffy Binding Protein (DBP) antigen DEKnull relevant for Plasmodium vivax malaria vaccine design.

Chen E, Salinas ND, Ntumngia FB, Adams JH, Tolia NH.

PLoS Negl Trop Dis. 2015 Mar 20;9(3):e0003644. doi: 10.1371/journal.pntd.0003644.

14.

Expression and serologic activity of a soluble recombinant Plasmodium vivax Duffy binding protein.

Fraser T, Michon P, Barnwell JW, Noe AR, Al-Yaman F, Kaslow DC, Adams JH.

Infect Immun. 1997 Jul;65(7):2772-7.

15.

Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1.

Dutta S, Dlugosz LS, Drew DR, Ge X, Ababacar D, Rovira YI, Moch JK, Shi M, Long CA, Foley M, Beeson JG, Anders RF, Miura K, Haynes JD, Batchelor AH.

PLoS Pathog. 2013;9(12):e1003840. doi: 10.1371/journal.ppat.1003840. Erratum in: PLoS Pathog. 2014 Jan;10(1). doi:10.1371/annotation/be0d67d1-314f-4654-8a2f-b668d1e32bbd. Ge, Xiopeng [corrected to Ge, Xiaopeng].

16.

Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection.

King CL, Michon P, Shakri AR, Marcotty A, Stanisic D, Zimmerman PA, Cole-Tobian JL, Mueller I, Chitnis CE.

Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8363-8. doi: 10.1073/pnas.0800371105.

17.

Antibody responses and avidity of naturally acquired anti-Plasmodium vivax Duffy binding protein (PvDBP) antibodies in individuals from an area with unstable malaria transmission.

Zakeri S, Babaeekhou L, Mehrizi AA, Abbasi M, Djadid ND.

Am J Trop Med Hyg. 2011 Jun;84(6):944-50. doi: 10.4269/ajtmh.2011.11-0001.

18.

Inhibitory properties of the antibody response to Plasmodium vivax Duffy binding protein in an area with unstable malaria transmission.

Ceravolo IP, Souza-Silva FA, Fontes CJ, Braga EM, Madureira AP, Krettli AU, Souza JM, Brito CF, Adams JH, Carvalho LH.

Scand J Immunol. 2008 Mar;67(3):270-8. doi: 10.1111/j.1365-3083.2007.02059.x.

19.

Anti-Plasmodium vivax duffy binding protein antibodies measure exposure to malaria in the Brazilian Amazon.

Cerávolo IP, Bruña-Romero O, Braga EM, Fontes CJ, Brito CF, Souza JM, Krettli AU, Adams JH, Carvalho LH.

Am J Trop Med Hyg. 2005 Jun;72(6):675-81.

20.

Naturally acquired antibodies to Plasmodium vivax Duffy binding protein (DBP) in Brazilian Amazon.

Souza-Silva FA, da Silva-Nunes M, Sanchez BA, Ceravolo IP, Malafronte RS, Brito CF, Ferreira MU, Carvalho LH.

Am J Trop Med Hyg. 2010 Feb;82(2):185-93. doi: 10.4269/ajtmh.2010.08-0580.

Items per page

Supplemental Content

Support Center